Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-07-2016 | Review – Clinical Oncology

Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer

Authors: Maria Luisa Gasparri, Giovanni Grandi, Daniele Bolla, Beat Gloor, Sara Imboden, Pierluigi Benedetti Panici, Michael D. Mueller, Andrea Papadia

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2016

Abstract

Purpose

Surgical cytoreduction remains a cornerstone in the management of patients with advanced and recurrent epithelial ovarian cancer. Parenchymal liver metastases determine stage VI disease and are commonly considered a major limit in the achievement of an optimal cytoreduction. The purpose of this manuscript was to discuss the rationale of liver resection and the morbidity related to this procedure in advanced and recurrent ovarian cancer.

Methods

A search of the National Library of Medicine’s MEDLINE/PubMed database until March 2015 was performed using the keywords: “ovarian cancer,” “hepatic,” “liver,” and “metastases.”

Results

In patients with liver metastases, hepatic resection is associated with a similar prognosis as stage IIIC patients. The length of the disease-free interval between primary diagnosis and occurrence of liver metastases, as well as residual disease after resection, is the most important prognostic factors. In addition, the number of liver lesions, resection margins, and the gynecologic oncology group performance status seem to play also an important role in determining outcome.

Conclusions

In properly selected patients, liver resections at the time of cytoreduction increase rates of optimal cytoreduction and improve survival in advanced-stage and recurrent ovarian cancer patients.

Abood G, Bowen M, Potkul R, Aranha G, Shoup M (2008) Hepatic resection for recurrent metastatic ovarian cancer. Am J Surg 195:370–373CrossRefPubMed

Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, Delvart V, Azoulay D, Bismuth H, Castaing D (2006a) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897–907CrossRefPubMedPubMedCentral

Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, Mantion G, Mentha G, Association Française de Chirurgie (2006b) Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244:524–535CrossRefPubMedPubMedCentral

Aletti GD, Podratz KC, Jones MB, Cliby WA (2006) Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer—a preliminary report. J Am Coll Surg 203:521–526CrossRefPubMed

Alseidi A, Helton WS, Espat NJ (2006) Does the literature support an indication for hepatic metastasectomy other than for colorectal primary? J Gastrointest Surg 10(1):99–104CrossRefPubMed

Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43CrossRefPubMed

Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ (2003) Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 10:52–58CrossRefPubMed

Bojalian MO, Machado GR, Swensen R, Reeves ME (2004) Radiofrequency ablation of liver metastasis from ovarian adenocarcinoma: case report and literature review. Gynecol Oncol 93(2):557–560CrossRefPubMed

Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72(3):278–287CrossRefPubMed

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol 20:1248–1259CrossRefPubMed

Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519–2529CrossRefPubMed

Chalkiadakis GE, Lasithiotakis KG, Petrakis I, Kourousis C, Georgoulias V (2005) Major hepatectomy and right hemicolectomy at the time of primary cytoreductive surgery for advanced ovarian cancer: report of a case. Int J Gynecol Cancer 15(6):1115–1119CrossRefPubMed

Chi DS, McCaughty K, Diaz JP et al (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933–1939CrossRefPubMed

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26–31CrossRefPubMed

Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244CrossRefPubMed

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D’Angelica MI, Barakat RR, Chi DS (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol Oncol 103(3):1083–1090CrossRefPubMed

Eisenkop SM, Spirtos NM, Lin WC (2006) Splenectomy in the context of primary cytoreductive operations for advanced epithelial cancer. Gynecol Oncol 100:344–348CrossRefPubMed

Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710CrossRefPubMed

Jacobs IA, Chang CK, Salti G (2003) Hepatic radiofrequency ablation of metastatic ovarian granulosa cell tumors. Am Surg 69(5):416–418PubMed

Kanas GP, Taylor A, Primrose JN et al (2012) Survival after liver resection in metastatic colorectal cancer: review and metaanalysis of prognostic factors. Clin Epidemiol 4:283–301PubMedPubMedCentral

Kehoe S, Hook J, Nankivell M et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249–257CrossRefPubMed

Kolev V, Pereira EB, Schwartz M, Sarpel U, Roayaie S, Labow D, Momeni M, Chuang L, Dottino P, Rahaman J, Zakashansky K (2014) The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer 24(1):70–74CrossRefPubMed

Learn PA, Bach PR (2010) A decade of mortality reductions in major oncologic surgery: the impact of centralization and quality improvement. Med Care 48:1041–1049CrossRefPubMed

Lee YT (1984) Breast carcinoma: pattern of recurrence and metastasis after mastectomy. Am J Clin Oncol 7:443–449CrossRefPubMed

Lim MC, Kang S, Lee KS, Han SS, Park SJ, Seo SS, Park SY (2009) The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol 112(1):28–34CrossRefPubMed

Loizzi V, Rossi C, Cormio G, Cazzolla A, Altomare D, Selvaggi L (2005) Clinical features of hepatic metastasis in patients with ovarian cancer. Int J Gynecol Cancer 15(1):26–31CrossRefPubMed

Magtibay PM, Adams PB, Silverman MB, Cha SS, Podratz KC (2006) Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol 102:369–374CrossRefPubMed

Mateo R, Singh G, Jabbour N, Palmer S, Genyk Y, Roman L (2005) Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors. Gynecol Oncol 97(1):266–270CrossRefPubMed

Meredith MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC (2003) Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol 89:16–21CrossRef

Nathan H, Cameron JL, Choti MA et al (2009) The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contribution and specificity of the relationship. J Am Coll Surg 208:528–538CrossRefPubMed

Neumann UP, Fotopoulou C, Schmeding M, Thelen A, Papanikolaou G, Braicu EI, Neuhaus P, Sehouli J (2012) Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases. Anticancer Res 32(10):4517–4521PubMed

Niu G, Shen C, Cui W, Li Q (2012) Hepatic resection is safe for metachronous hepatic metastases from ovarian cancer. Cancer Biol Med 9:182–187PubMedPubMedCentral

Papadia A, Morotti M (2013) Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature. Arch Gynecol Obstet 287:733–741CrossRefPubMed

Papadia A, Moya Y, Rodgers SE et al (2011) Surgical resection of recurrent upper abdominal cervical cancer: a case report and review of the literature. Gynecol Oncol Case Rep 1:8–9CrossRefPubMedPubMedCentral

Pekmezci S, Saribeyoglu K, Aytac E, Arvas M, Demirkiran F, Ozguroglu M (2010) Surgery for isolated liver metastasis of ovarian cancer. Asian J Surg 30(2):83–88CrossRef

Peterhans M, vom Berg A A, Dagon B et al (2011) A navigation system for open liver surgery: design, workflow and first clinical applications. Int J Med Robot 7:7–16CrossRefPubMed

Prat J (2015) FIGO Committee on Gynecologic Oncology. Abridged republication of FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum. Cancer. doi:10.1002/cncr.29524

Roh HJ, Kim DY, Joo WD, Yoo HJ, Kim JH, Kim YM, Kim YT, Nam JH (2011) Hepatic resection as part of secondary cytoreductive surgery for recurrent ovarian cancer involving the liver. Arch Gynecol Obstet 284(5):1223–1229CrossRefPubMed

Rose PG, Piver MS, Tsukada Y, Lau TS (1989) Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 64:1508–1513CrossRefPubMed

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29CrossRefPubMed

Tangjitgamol S, Levenback CF, Beller U, Kavanagh JJ (2004) Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer 14(3):399–422CrossRefPubMed

Veereman G, Robays J, Verleye L et al (2015) Pooled analysis of the surgical treatment for colorectal cancer liver metastases. Crit Rev Oncol/Hematol 94:122–135CrossRef

Vergote I, Tropé CG, Amant FA et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIc–IV ovarian cancer. N Engl J Med 363:943–953CrossRefPubMed

Weitz J, Blumgart LH, Fong Y, Jarnagin WR, D’Angelica M, Harrison LE et al (2005) Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg 241:269–276CrossRefPubMedPubMedCentral

Winter WE III, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26:83–89CrossRefPubMed

Yoon SS, Jarnagin WR, Fong Y, DeMatteo RP, Barakat RR, Blumgart LH, Chi DS (2003) Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol 91(2):383–388CrossRefPubMed

Zang RY, Harter P, Chi DS et al (2011) Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer 105:890–896CrossRefPubMedPubMedCentral

Title: Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer
Authors: Maria Luisa Gasparri
Giovanni Grandi
Daniele Bolla
Beat Gloor
Sara Imboden
Pierluigi Benedetti Panici
Michael D. Mueller
Andrea Papadia
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2016
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2090-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2016

Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study

Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia

Exploring an herbal “wonder cure” for cancer: a multidisciplinary approach

Oroxylin A, a natural anticancer flavonoid compound, induces differentiation of t(8;21)-positive Kasumi-1 and primary acute myeloid leukemia cells

Rapid staining and imaging of subnuclear features to differentiate between malignant and benign breast tissues at a point-of-care setting

Membrane microparticles: shedding new light into cancer cell communication

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page